Skip to main content

Table 3 Antimicrobial resistance rates of clinical isolates of community-acquired (CA), healthcare-associated (HCA), and nosocomial K. pneumoniae bacteremia

From: Clinical characteristics, antimicrobial resistance and capsular types of community-acquired, healthcare-associated, and nosocomial Klebsiella pneumoniae bacteremia

Variable CA (n = 70) HCA (n = 102) Nosocomial (n = 165) p value
CA vs. HCA HCA vs. Nosocomial CA vs. Nosocomial
Amikacin 0 (0.0) 1 (1.0) 7 (4.2) 1.000 0.160 0.107
Gentamicin 1 (1.4) 15 (14.7) 35 (21.2) 0.003 0.185 < 0.001
Cefuroxime 2 (2.9) 23 (22.5) 67 (40.6) < 0.001 0.002 < 0.001
Ceftriaxone 1 (1.4) 12 (11.8) 52 (31.5) 0.016 < 0.001 < 0.001
Cefepime 0 (0.0) 6 (5.9) 24 (14.5) 0.082 0.029 < 0.001
Ciprofloxacin 1 (1.4) 11 (10.8) 49 (29.7) 0.029 < 0.001 < 0.001
Levofloxacin 1 (1.4) 11 (10.8) 48 (29.1) 0.029 < 0.001 < 0.001
Ertapenem 0 (0.0) 7 (6.9) 27 (16.4) 0.042 0.024 < 0.001
Imipenem 0 (0.0) 1 (1.0) 14 (8.5) 1.000 0.011 0.012
Tigecycline 2 (2.9) 3 (2.9) 5 (3.0) 1.000 1.000 1.000
Trimethoprim-sulfamethoxazole 5 (7.1) 25 (24.5) 61 (37.0) 0.003 0.034 < 0.001
Wild-type antibiotic susceptibilitya 60 (85.7) 67 (65.7) 78 (47.3) 0.003 0.003 < 0.001
Multidrug resistanceb 4 (5.7) 24 (23.5) 69 (41.8) 0.002 0.002 < 0.001
  1. Data are presented as number (%) of isolates resistant to the antibiotic indicated, unless stated otherwise
  2. aWild-type antibiotic susceptibility was defined in the isolates as susceptibility to all antibiotics except for ampicillin
  3. bMultidrug resistance was defined in the isolates as nonsusceptibility to at least one agent in three or more antimicrobial categories